NLS Pharmaceutics Ltd. — Capital/Financing Update 2021

Nov 1, 2021

CORRESP 1 filename1.htm

NLS Pharmaceutics Ltd.

Alter Postplatz 2

CH-6370 Stans, Switzerland

November 1, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement No. 333-260435 on Form F-1 (the “Registration Statement”)

Ladies and Gentlemen:

NLS Pharmaceutics Ltd. (the “ Registrant ”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Securities Act ”), so that it may become effective on November 3, 2021 at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.

Very truly yours,
nls pharmaceutics LTD.
By:	/s/ Alexander Zwyer
	Alexander Zwyer, Chief Executive Officer

Field: Page; Sequence: 1; Options: Last

Field: /Page